Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Read C, Nyimanu D, Williams TL, Huggins DJ, Sulentic P, Macrae RGC, Yang P, Glen RC, Maguire JJ, Davenport AP.

Pharmacol Rev. 2019 Oct;71(4):467-502. doi: 10.1124/pr.119.017533.

PMID:
31492821
2.

Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor.

Nyimanu D, Kuc RE, Williams TL, Bednarek M, Ambery P, Jermutus L, Maguire JJ, Davenport AP.

Peptides. 2019 Aug 28;121:170139. doi: 10.1016/j.peptides.2019.170139. [Epub ahead of print]

3.

Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo.

Read C, Yang P, Kuc RE, Nyimanu D, Williams TL, Glen RC, Holt LJ, Arulanantham H, Smart A, Davenport AP, Maguire JJ.

Basic Clin Pharmacol Toxicol. 2019 Mar 22. doi: 10.1111/bcpt.13227. [Epub ahead of print]

4.

A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension.

Yang P, Read C, Kuc RE, Nyimanu D, Williams TL, Crosby A, Buonincontri G, Southwood M, Sawiak SJ, Glen RC, Morrell NW, Davenport AP, Maguire JJ.

Br J Pharmacol. 2019 May;176(9):1206-1221. doi: 10.1111/bph.14603. Epub 2019 Apr 1.

5.

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.

Davenport AP, Kuc RE, Southan C, Maguire JJ.

Physiol Res. 2018 Jun 27;67(Suppl 1):S37-S54. Review.

6.

[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.

Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC, Cheriyan J, Wilkinson IB, Davenport AP, Maguire JJ.

Front Neurosci. 2017 Feb 28;11:92. doi: 10.3389/fnins.2017.00092. eCollection 2017.

7.

Elimination of the unnecessary: Intra- and extracellular signaling by anionic phospholipids.

Kagan VE, Bayır H, Tyurina YY, Bolevich SB, Maguire JJ, Fadeel B, Balasubramanian K.

Biochem Biophys Res Commun. 2017 Jan 15;482(3):482-490. doi: 10.1016/j.bbrc.2016.11.005. Epub 2017 Feb 3. Review.

8.

Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension.

Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP.

Circulation. 2017 Mar 21;135(12):1160-1173. doi: 10.1161/CIRCULATIONAHA.116.023218. Epub 2017 Jan 30.

9.

Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature.

Kennedy AJ, Yang P, Read C, Kuc RE, Yang L, Taylor EJ, Taylor CW, Maguire JJ, Davenport AP.

J Am Heart Assoc. 2016 Oct 14;5(10). pii: e004421.

10.

Known unknowns of cardiolipin signaling: The best is yet to come.

Maguire JJ, Tyurina YY, Mohammadyani D, Kapralov AA, Anthonymuthu TS, Qu F, Amoscato AA, Sparvero LJ, Tyurin VA, Planas-Iglesias J, He RR, Klein-Seetharaman J, Bayır H, Kagan VE.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Jan;1862(1):8-24. doi: 10.1016/j.bbalip.2016.08.001. Epub 2016 Aug 4. Review.

11.

Cardiac action of the first G protein biased small molecule apelin agonist.

Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP.

Biochem Pharmacol. 2016 Sep 15;116:63-72. doi: 10.1016/j.bcp.2016.07.018. Epub 2016 Jul 27.

12.

Endothelin.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ.

Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833. Review.

13.

Evidence for biased agonists and antagonists at the endothelin receptors.

Maguire JJ.

Life Sci. 2016 Aug 15;159:30-33. doi: 10.1016/j.lfs.2016.02.069. Epub 2016 Feb 17. Review.

14.

Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Yang P, Maguire JJ, Davenport AP.

Trends Pharmacol Sci. 2015 Sep;36(9):560-7. doi: 10.1016/j.tips.2015.06.002. Epub 2015 Jul 1. Review.

15.

Endothelin receptors and their antagonists.

Maguire JJ, Davenport AP.

Semin Nephrol. 2015 Mar;35(2):125-36. doi: 10.1016/j.semnephrol.2015.02.002. Review.

16.

LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal.

Shaikh LH, Zhou J, Teo AE, Garg S, Neogi SG, Figg N, Yeo GS, Yu H, Maguire JJ, Zhao W, Bennett MR, Azizan EA, Davenport AP, McKenzie G, Brown MJ.

J Clin Endocrinol Metab. 2015 Jun;100(6):E836-44. doi: 10.1210/jc.2015-1734. Epub 2015 Apr 27.

17.

Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP.

Hypertension. 2015 Apr;65(4):834-40. doi: 10.1161/HYPERTENSIONAHA.114.05099. Epub 2015 Feb 23.

18.

Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.

Maguire JJ, Davenport AP.

Br J Pharmacol. 2014 Dec;171(24):5555-72. doi: 10.1111/bph.12874. Epub 2014 Nov 24. Review.

19.

Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis.

Ooi CY, Sutcliffe MP, Davenport AP, Maguire JJ.

Life Sci. 2014 Nov 24;118(2):424-9. doi: 10.1016/j.lfs.2014.03.027. Epub 2014 Apr 8.

20.

Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.

Kuc RE, Maguire JJ, Siew K, Patel S, Derksen DR, Margaret Jackson V, O'Shaughnessey KM, Davenport AP.

Life Sci. 2014 May 2;102(2):134-8. doi: 10.1016/j.lfs.2014.03.011. Epub 2014 Mar 15.

21.

Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.

Kuc RE, Carlebur M, Maguire JJ, Yang P, Long L, Toshner M, Morrell NW, Davenport AP.

Life Sci. 2014 Nov 24;118(2):391-6. doi: 10.1016/j.lfs.2014.02.020. Epub 2014 Feb 26.

22.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

23.

The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.

Maguire JJ, Jones KL, Kuc RE, Clarke MC, Bennett MR, Davenport AP.

Cardiovasc Res. 2014 Mar 1;101(3):513-21. doi: 10.1093/cvr/cvt333. Epub 2013 Dec 9.

24.

Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation.

Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC.

Immunity. 2013 Feb 21;38(2):285-95. doi: 10.1016/j.immuni.2013.01.008. Epub 2013 Feb 7.

25.

Radioligand binding assays and their analysis.

Maguire JJ, Kuc RE, Davenport AP.

Methods Mol Biol. 2012;897:31-77. doi: 10.1007/978-1-61779-909-9_3.

PMID:
22674160
26.

Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.

Maguire JJ, Kuc RE, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):681-6. doi: 10.1016/j.lfs.2012.05.008. Epub 2012 May 23.

27.

The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.

Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):743-8. doi: 10.1016/j.lfs.2012.03.022. Epub 2012 Mar 28.

28.

Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.

Maguire JJ, Kuc RE, Pell VR, Green A, Brown M, Kumar S, Wehrman T, Quinn E, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):544-9. doi: 10.1016/j.lfs.2012.03.021. Epub 2012 Mar 27.

29.

Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice.

Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):716-22. doi: 10.1016/j.lfs.2012.02.003. Epub 2012 Feb 18.

30.

Inotropic action of the puberty hormone kisspeptin in rat, mouse and human: cardiovascular distribution and characteristics of the kisspeptin receptor.

Maguire JJ, Kirby HR, Mead EJ, Kuc RE, d'Anglemont de Tassigny X, Colledge WH, Davenport AP.

PLoS One. 2011;6(11):e27601. doi: 10.1371/journal.pone.0027601. Epub 2011 Nov 22.

31.

Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Ling L, Maguire JJ, Davenport AP.

Br J Pharmacol. 2013 Jan;168(2):283-95. doi: 10.1111/j.1476-5381.2011.01786.x. Review.

32.

Pharmacology of renal endothelin receptors.

Davenport AP, Maguire JJ.

Contrib Nephrol. 2011;172:1-17. doi: 10.1159/000328678. Epub 2011 Aug 30. Review.

PMID:
21893985
33.

Discovery of a competitive apelin receptor (APJ) antagonist.

Macaluso NJ, Pitkin SL, Maguire JJ, Davenport AP, Glen RC.

ChemMedChem. 2011 Jun 6;6(6):1017-23. doi: 10.1002/cmdc.201100069. Epub 2011 May 10.

PMID:
21560248
34.

Chemokine receptor CCR5: from AIDS to atherosclerosis.

Jones KL, Maguire JJ, Davenport AP.

Br J Pharmacol. 2011 Apr;162(7):1453-69. doi: 10.1111/j.1476-5381.2010.01147.x. Review.

35.

International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function.

Kirby HR, Maguire JJ, Colledge WH, Davenport AP.

Pharmacol Rev. 2010 Dec;62(4):565-78. doi: 10.1124/pr.110.002774. Review.

36.

Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.

Pitkin SL, Maguire JJ, Kuc RE, Davenport AP.

Br J Pharmacol. 2010 Aug;160(7):1785-95. doi: 10.1111/j.1476-5381.2010.00821.x.

37.

Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1.

Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ.

Can J Physiol Pharmacol. 2010 Jun;88(6):644-51. doi: 10.1139/Y10-041.

38.

International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function.

Pitkin SL, Maguire JJ, Bonner TI, Davenport AP.

Pharmacol Rev. 2010 Sep;62(3):331-42. doi: 10.1124/pr.110.002949. Epub 2010 Jul 6. Review.

PMID:
20605969
39.

Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver.

Johnström P, Fryer TD, Richards HK, Maguire JJ, Clark JC, Pickard JD, Davenport AP.

Br J Pharmacol. 2010 Feb;159(4):812-9. doi: 10.1111/j.1476-5381.2010.00641.x.

40.

Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation.

Mitchell JD, Kuc RE, Maguire JJ, Davenport AP.

Vet J. 2010 Oct;186(1):106-9. doi: 10.1016/j.tvjl.2009.06.026. Epub 2009 Aug 14.

PMID:
19683464
41.

[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease.

Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP.

Hypertension. 2009 Sep;54(3):598-604. doi: 10.1161/HYPERTENSIONAHA.109.134619. Epub 2009 Jul 13.

PMID:
19597036
42.

Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Mitchell JD, Maguire JJ, Davenport AP.

Br J Pharmacol. 2009 Sep;158(1):87-103. doi: 10.1111/j.1476-5381.2009.00252.x. Epub 2009 Jun 10. Review.

43.

International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature.

Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP.

Pharmacol Rev. 2009 Mar;61(1):1-8. doi: 10.1124/pr.109.001107. Review.

44.

Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system.

Mitchell JD, Maguire JJ, Kuc RE, Davenport AP.

Cardiovasc Res. 2009 Feb 1;81(2):353-61. doi: 10.1093/cvr/cvn302. Epub 2008 Nov 5.

PMID:
18987052
45.

Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration.

Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR.

Circ Res. 2008 Jun 20;102(12):1529-38. doi: 10.1161/CIRCRESAHA.108.175976. Epub 2008 May 22.

PMID:
18497329
46.

Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function.

Maguire JJ, Kuc RE, Kleinz MJ, Davenport AP.

Peptides. 2008 May;29(5):735-42. Epub 2007 Aug 26.

PMID:
17905478
47.

Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system.

Mead EJ, Maguire JJ, Kuc RE, Davenport AP.

Br J Pharmacol. 2007 Aug;151(8):1143-53. Epub 2007 May 21. Review.

48.

Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation.

Singh G, Maguire JJ, Kuc RE, Skepper JN, Fidock M, Davenport AP.

Br J Pharmacol. 2006 Dec;149(7):838-44. Epub 2006 Oct 16.

49.
50.

Endothelin.

Davenport AP, Maguire JJ.

Handb Exp Pharmacol. 2006;(176 Pt 1):295-329. Review.

PMID:
16999223

Supplemental Content

Loading ...
Support Center